SYSTEMS BIOLOGY RESEARCH
Vivia's innovative research model consists of analyzing the effect of thousands of existing drugs directly on a patient's standard biological sample, such as for example blood or bone marrow.
Vivia is worldwide pioneer in screening and profiling thousands of drugs on patients' blood samples, an innovative Systems Biology research model, truly "translational", which has allowed implementing for the first time in the world the ExviTech© Technology Platform, owned by Vivia.
In the first application of this technology within the scope of hematologic cancers (leukemia, lymphoma and multiple myeloma), this ability has been used to measure the efficacy of drugs when selectively eliminating only carcinogenic cells from the sample, without affecting the healthy cells.
